27 July 2018
Visiongain’ has launched a new pharma report Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies
Hereditary Angioedema is a disorder characterized by reoccurring phenomena of severe swelling. Limbs, face airway and intestinal tract are the common areas of the body that swells up in this condition. This report evaluates the global market of hereditary angioedema in regions such as North America, Latin America, Europe, Asia-Pacific and the Middle East and Africa. Furthermore, this report provides detailed overview of various medical hereditary angioedema segments such as drug class, route of administration and distribution channel.
The lead analyst of the report commented “Hereditary angioedema (HAE) is a rare disease and the diagnosis of HAE is challenging in children. Lack of awareness, diagnostic testing limitations, and communication difficulties along with the differential diagnosis of the symptoms of this disorder contribute to this challenge. Delay in diagnosis leads to sub-optimal treatment of symptoms and reduced quality of life.”
Leading companies featured in the report include BioCryst Pharmaceuticals, Inc., CSL Limited, iBio, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV, Santarus, Inc., Shire PLC
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.